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Background: Identification of melanoma patients at high risk for recurrence and monitoring for recurrence are
critical for informed management decisions. We hypothesized that serum microRNAs (miRNAs) could provide
prognostic information at the time of diagnosis unaccounted for by the current staging system and could be useful
in detecting recurrence after resection.
Methods: We screened 355 miRNAs in sera from 80 melanoma patients at primary diagnosis (discovery cohort)
using a unique quantitative reverse transcription-PCR (qRT-PCR) panel. Cox proportional hazard models and
Kaplan-Meier recurrence-free survival (RFS) curves were used to identify a miRNA signature with prognostic
potential adjusting for stage. We then tested the miRNA signature in an independent cohort of 50 primary
melanoma patients (validation cohort). Logistic regression analysis was performed to determine if the miRNA
signature can determine risk of recurrence in both cohorts. Selected miRNAs were measured longitudinally in
subsets of patients pre-/post-operatively and pre-/post-recurrence.
Results: A signature of 5 miRNAs successfully classified melanoma patients into high and low recurrence risk
groups with significant separation of RFS in both discovery and validation cohorts (p = 0.0036, p = 0.0093,
respectively). Significant separation of RFS was maintained when a logistic model containing the same signature set
was used to predict recurrence risk in both discovery and validation cohorts (p < 0.0001, p = 0.033, respectively).
Longitudinal expression of 4 miRNAs in a subset of patients was dynamic, suggesting miRNAs can be associated
with tumor burden.
Conclusion: Our data demonstrate that serum miRNAs can improve accuracy in identifying primary melanoma
patients with high recurrence risk and in monitoring melanoma tumor burden over time.
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Melanoma remains a highly morbid disease in the Uni-
ted States, and its incidence has continued to rise over
the past few decades [1]. The toll in terms of “life-years
lost” in melanoma is the highest of all solid tumors in
the United States [2]. Recurrence risk varies by stage,
with estimated recurrence rates of up to 30% for* Correspondence: iman.osman@nyumc.org
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reproduction in any medium, provided the orlocalized melanoma and 60% for regional nodal disease
[3]. Both the identification of patients at high risk for re-
currence at primary diagnosis and the early detection of
disease relapse are critical for informed management
decisions.
The current standard of care for determining the prog-
nosis of melanoma patients with localized disease and
guiding post-operative follow-up both have limitations.
In using prognostic factors, such as primary tumor
thickness, ulceration, mitotic rate, and lymph node in-
volvement, the American Joint Committee on Cancer
(AJCC) staging system is able to provide first-line strati-
fication for melanoma-specific survival [4]. However, theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in the prognosis of melanoma, and there remains unex-
plained heterogeneity within each stage. Additionally,
despite the benefit of early detection of locoregional and
distant metastases amenable to curative resection [3,5],
there is no consensus on either the selection or timing
of imaging studies and laboratory tests for use in follow-
up [6]. This is in part due to the limited sensitivity and
specificity of available imaging modalities and blood
tests, coupled with considerable economic cost [7].
Due to the routine collection and facility of obtaining
blood samples at multiple time points, blood-based bio-
markers are a logical and cost effective source in the
search for non-invasive biomarkers. Although assess-
ment of circulating markers for prognosis and surveil-
lance has been part of the standard of care in breast and
colon cancer management for several years [8], no such
markers exist for early-stage melanoma. While many
molecules have been studied as biomarkers for use in
melanoma [9-11], none have been developed into a clin-
ically relevant assay. Currently, serum lactate dehydro-
genase is the only blood-based marker routinely used in
melanoma, but it has only shown prognostic significance
in advanced disease [4,10,11] and is rarely the sole indi-
cator of recurrence [12]. There remains a need to de-
velop methods to accurately determine recurrence risk
of primary melanoma patients and improve follow-up
for early detection of relapse.
MicroRNAs (miRNAs) are small, non-coding RNAs
that negatively regulate gene expression at the post-
transcriptional level [13]. Given their implication in
tumorigenesis, tissue-specific dysregulation in cancer
[14], and presence in human serum in an extremely
stable form resistant to RNase digestion, harsh condi-
tions, extended storage, and multiple freeze-thaw cycles
[15], miRNAs have emerged as a novel source of blood-
based reporters of cancer progression. Studies assessing
serum or plasma miRNAs as biomarkers in a variety of
cancers have largely focused on distinguishing cancer
patients from control subjects [16,17]. While there is
growing interest in evaluating the prognostic potential of
circulating miRNAs [18-21], to the best of our know-
ledge, no study has specifically examined the association
between serum-based miRNAs and recurrence risk in
primary melanoma patients.
Methods
Study population
A total of 140 primary cutaneous melanoma patients
who presented to New York University (NYU) Langone
Medical Center for surgical resection of AJCC stage I-III
disease were studied. Pre-treatment sera were collected
at the time of initial diagnosis. A discovery cohort of 80
patients (discovery cohort) and an independent cohortof 50 patients (validation cohort) were used to construct
prognostic models. Sera collected at the time of primary
diagnosis and recurrence were available for a subset
of patients (n = 17). All patients had histologically
confirmed melanoma [22]. Relevant demographic and
clinicopathological data were obtained from the pro-
spectively maintained NYU Interdisciplinary Melanoma
Cooperative Group (IMCG) database [22]. Both locore-
gional (stage III) and distant metastases (stage IV) were
defined as recurrences. Additionally, an independent set
of 10 melanoma patients had sera collected before and
7–14 days after surgical resection. The NYU Institu-
tional Review Board approved the study and informed
consent was obtained from all patients at the time of
enrollment.
All serum samples were collected in 10-mL BD serum
tubes, stored immediately at 4°C, and then centrifuged
at 10°C for 10 minutes at 1,500 x g. The supernatant
serum was then aliqouted into 1.5 mL cryovials and
stored at −80°C until further use.miRNA extraction, quantitative reverse transcription-PCR
(qRT-PCR) screening and individual evaluation
Total RNA was extracted from sera using the Qiagen
miRNeasyW Mini Kit using manufacturer’s instructions
with minor modifications and eluted with 50μL of
RNase-free water. Reverse transcription (RT) was per-
formed using 8 μl RNA in 40 μl reactions using the miR-
CURY LNA™ Universal RT microRNA PCR system
(Exiqon, Denmark). cDNA was diluted 50x and ampli-
fied in 10 μl PCR reactions following manufacturer’s
instructions by qPCR on a unique Pick & Mix discovery
panel containing 355 miRNA assays and positive and
negative controls. Negative controls excluding template
from the RT reaction were performed and profiled like
the samples. Amplification was performed in 384 well
plates in a LightCyclerW 480 Real-Time PCR System
(Roche) and curves were analyzed using Roche LC
software.
Notably, the qPCR platform (Exiqon) utilized has been
reported to be the most sensitive and specific qPCR plat-
form available when analyzing ultra low miRNA levels
(200 copies or less) as found in serum and other biofluid
samples [23]. The miRCURY platform has a very high
degree of linearity (r2 ≥ 0.9) across four log scales of
miRNA copies for all assays, indicating good perform-
ance of the panel at very low miRNA concentrations.
True sensitivity of the platform is maximized because of
two features. First, cDNA synthesis is carried out using a
universal approach that allows all miRNAs in a sample
to be synthesized equally. Second, LNAs are incorpo-
rated into the PCR primers making the PCR assay per-
formance independent of GC content, which can
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amplified and accurately quantified.
Of the 355 miRNA assays, 170 miRNAs were included
in analysis as they had Ct ≤ 40 and were detected with 5
Cts less than the no RT template included negative con-
trol in greater than two-thirds of patients. Expression
data for 2 patients did not pass the quality control (QC)
criteria and were not included in further analysis. Add-
itionally, 1 patient had missing expression data for miR-
199a-5p and was not included in analyses of models
containing this miRNA.
A panel of 11 miRNAs (miR-15b, -23b, -30d, -33a, -103,
-150, -199a-5p, -423-5p, -424, -425 and let-7d) identified as
potential predictors of recurrence in multivariable models
were selected for evaluation in the validation cohort using
individual qRT-PCR assays. RT using 2 μl RNA in 10 μl
reactions was performed in duplicate, amplified by qPCR
and analyzed following the protocol described above.
Longitudinal evaluation of miRNA expression
In exploring the potential of serum miRNAs as markers of
melanoma recurrence, we elected to use a targeted ap-
proach to select miRNAs for study in pre-/post-operative
and pre-/post-recurrence samples. We included several of
the miRNAs that we identified as having prognostic po-
tential in our discovery phase and were further evaluated
in the validation cohort (i.e. miR-103, -191, -423-5p, -425).
We did not limit ourselves to using only those miRNAs
included in the recurrence risk signature as markers of
prognosis may not translate into markers of disease detec-
tion. Instead, we focused on miRNAs from our prioritized
panel that had previously supported roles in cancer pro-
gression and/or diagnostic utility. For example, high levels
of miR-103 are associated with metastasis and poor out-
come in breast cancer patients and functionally, mir-103
confers migratory capacities in vitro [24]. Elevated expres-
sion of miR-191 promotes epithelial-to-mesenchymal
transition in hepatocellular carcinoma [25]. miR-423-5p
was identified as part of a 5-miRNA signature for gastric
cancer diagnosis [26]. We also chose to include one
miRNA, miR-425, whose functional relevance in cancer
was previously unexplored to avoid eliminating potentially
useful markers. Additionally, we selected miRNAs that
have well supported roles in melanoma progression (i.e.
miR-182, -221, -222) as demonstrated by tissue-based
studies [27,28].
Total RNA was extracted using the miRVana Paris isola-
tion system (Ambion, USA) following the manufacturer’s
protocol with the addition of an acid/phenol/chloroform
extraction in a final elute of 100 μl. RT was performed
using 2.5 μl miRNA in a final volume of 10 μl following
manufacturer’s instructions using TaqMan MicroRNA Re-
verse Transcription kit (Applied Biosystems, USA). qRT-
PCR was performed in triplicate on a MyIQ Single ColorReal Time PCR detection system (Bio-Rad, USA), using
1.33 μl cDNA, 1 μl miRNA-specific TaqManW primer and
1x Hotmaster Master mix containing Taq DNA polymer-
ase (5 Prime, USA) and dNTP Mix (Promega, USA) in a
final volume of 20 μl per reaction. The amplification
protocol was: 95°C for 17 min, 40 cycles at 95°C for 15 sec
followed by 60°C for 1 min.
Statistical methods
Using the discovery cohort (n=80), miRNAs were first
ranked by univariate association of expression level for each
miRNA with recurrence-free survival (RFS) via Cox propor-
tional hazards regression analysis with adjustment for
tumor stage. Top-ranking miRNAs were used as candidates
to be included in the multivariate Cox proportional hazards
model. The 5 miRNA-signature was selected by minimizing
Akaike’s information criterion (AIC) of the multivariate
Cox proportional hazards model through stepwise selec-
tion [29,30]. The linear combination of model predictors
weighted by regression coefficients was defined as the risk
score. A cutoff of the risk score was chosen to separate
patients into high and low recurrence risk groups [31].
Kaplan-Meier survival curves for the resulting groups were
plotted, and log-rank test was used to compare the two
curves. To test the classifier, regression coefficients of the
Cox model were applied to the validation cohort (n=50) to
obtain a risk score, and the same cutoff was used to predict
RFS in the validation cohort.
The identified miRNA signature set was also evaluated
for its utility in predicting 3-year RFS by logistic regression
model using recurred patients (n = 25) and non-recurred
patients (n = 44) with ≥3 years follow-up from the discov-
ery cohort as cases and controls, respectively [32]. An op-
timal risk score cutoff using the Youden Index of the
Receiver Operating Characteristic (ROC) curve was
chosen to classify patients into high and low risk groups.
Kaplan-Meier survival curves and log-rank tests were used
to compare the RFS distributions of the two groups. The
logistic model was used to predict recurrence risk in the
validation cohort of 20 recurred and 16 non-recurred
patients with ≥3 years follow-up. The same risk score cut-
off was used to classify patients.
As a subset analysis to demonstrate the utility of serum
miRNAs beyond tumor stage, we built a logistic model
using the panel of 11 prioritized miRNAs in all stage II
patients and examined its ability to distinguish patients
with and without recurrence by cross validation, and exam-
ined the RFS difference using Kaplan-Meier curves between
the predicted high vs. low risk groups. Longitudinal changes
in miRNA expression were assessed using two-sided Stu-
dent’s t tests (p <0.05). All statistical analyses were per-
formed in R 2.12.0.
The reported results are based on Ct values that passed
QC but without further normalization. To assess the
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expression were explored (i.e. median normalization: shift
Ct values on each panel by additive constants such that the
medians of miRNA expression are the same across panels).
The resulting candidate set of miRNAs identified were
similar to those obtained when data were not
normalized; moreover, selected classifiers worked well
whether Ct values were normalized or not, indicating the
robustness of the developed models.
Results
Clinical and pathologic characteristics of the 130
patients used in prognostic modeling are presented in
Table 1. Recurrence status stratified by stage for patients
in the discovery and validation cohorts is shown in
Table 2. The median time of follow-up for survivors was
42.5 months (range, 17–237 months).
Cox proportional hazards model identifies a miRNA
signature with prognostic potential
We screened serum samples of the discovery cohort using
a qPCR platform of 355 miRNAs, of which data for 170
miRNAs were available for at least 67% samples. A multi-
variate Cox proportional hazards model for RFS was identi-
fied, which contains 5 miRNAs (miR-150, -15b, -199a-5p,Table 1 Baseline characteristics of melanoma patients
Variable Melanoma patients
(n = 140)N (%)
Age at diagnosis, years
Median 59
Gender
Male 82 (59)
Female 58 (41)
Thickness, mm
Median (range) 2 (0.27-28)
Ulceration
Present 49 (35)
Absent 91 (65)
Mitosis
Absent 27 (19)
Present 97 (69)
Unclassified 16 (11)
Histological type
Superficial Spreading 54 (39)
Nodular 44 (31)
Othera 25 (18)
Unclassified 17 (12)
NOTE. Percentages may not sum to 100% as a result of rounding
aOther includes acral lentiginous melanoma, desmoplastic melanoma and
lentigo maligna.-33a, -424) with adjustment for stage (Table 3). The linear
combination of model predictors weighted by regression
coefficients was defined as the risk score. Motivated by
Satzger et al. [31], a cutoff was chosen to separate patients
into high and low recurrence risk groups aimed at maxi-
mizing the log-rank statistic (sensitivity =0.84, specificity =
0.76; high risk, n= 34, low risk, n=46). Kaplan-Meier ana-
lysis revealed that the two groups have a significant separ-
ation in RFS (p=0.0036, Figure 1A). The model was
applied to predict recurrence risk in the validation cohort,
and the same cutoff was used to separate patients into high
and low recurrence risk groups (sensitivity =0.84, specifi-
city =0.60; high risk n=28, low risk n=21). Kaplan-Meier
analysis indicated that the resulting RFS distributions were
again significantly different (p=0.009, Figure 1B).
Logistic regression analysis confirms prognostic potential
of miRNA-based risk model for 3-year RFS
The performance of the 5 miRNAs identified by Cox ana-
lysis was then evaluated by logistic regression analysis. In
the discovery cohort, the addition of the 5-miRNA signa-
ture to a base risk model containing stage as a predictor
improved the performance of the classifier, demonstrated
by an increase in the area under the ROC curve (AUC)
from AUC=0.77 (95% CI, 0.66-0.89) of stage alone to
AUC=0.84 (95% CI, 0.73-0.94) with the 5-miRNA signa-
ture. Using a cutoff to separate the discovery cohort into
high and low recurrence risk groups (sensitivity = 84%,
specificity = 64%), the two groups had significant separ-
ation of RFS (p< 0.0001, Figure 2A). The model was ap-
plied to predict recurrence in the validation cohort, and
the same cutoff was used to define high and low recur-
rence risk groups (sensitivity = 95%, specificity = 41%). Per-
formance of the classifier was maintained, with significant
separation of RFS (p= 0.033, Figure 2B).
A signature of candidate miRNAs as predictors of
recurrence in stage II melanoma supports that miRNA
signatures might have prognostic utility beyond tumor
stage
Recurrence status among all stage II patients was relatively
balanced, with 19 recurred and 20 non-recurred afterTable 2 Recurrence status of melanoma patients
stratified by stage
Stage Discovery Cohort Validation Cohort
No recurrence Recurrence No recurrence Recurrence
I 34 5 10 0
II 13 7 16 12
IIIa 8 13 4 8
Totals 55 25 30 20
aIncludes 1 patient diagnosed with stage III melanoma, but did not have blood
drawn until time of recurrence with stage IV disease.
Table 3 Covariates included in multivariate Cox
proportional hazards models
Covariate p-value HR (95% CI)
Stage II 0.0108 4.862 (1.442-16.397)
Stage III 4.1e-05 9.366 (3.125-27.287)
miR-150 0.1469 1.297 (0.913-1.843)
miR-15b 0.0159 0.437 (0.223-0.856)
miR-199a-5p 0.1383 1.375 (0.903-2.094)
miR-33a 0.1099 0.720 (0.481-1.077)
miR-424 0.0094 1.821 (1.158-2.862)
Abbreviation: HR: Hazard ratio; CI: confidence interval.
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group analyses as proof-of-principle that serum-based
miRNAs have prognostic potential beyond stage. Stage II
patients pose a particularly difficult clinical challenge.
Though still localized melanoma, stage II patients have
significantly lower survival rates than stage I patients, with
5-year survival rates from 53% to 82% compared to >90%,
respectively [33]. In our cohort of stage II patients, a logis-
tic risk model with thickness alone was able to distinguish
recurred from non-recurred patients with an AUC=0.75
(p= 0.06). With the addition of 3 of the miRNAs priori-
tized for further evaluation (miR-423-5p, -424, -199a-5p),
the performance of the classifier improved (AUC=0.89,
Figure 3A), and 2 of the miRNAs were significant predic-
tors of recurrence in the model (miR-423-5p: Odds Ratio
(OR), 0.038; 95% CI, 0.0031-0.46; p = 0.008; miR-424: OR,
3.64; 95% CI, 1.19-11.1; p = 0.018). Four-fold cross valid-
ation demonstrated an AUC=0.81. Using Youden’s index
of ROC curve as a cutoff to separate patients into high
and low recurrence risk groups (sensitivity = 94%,Figure 1 Kaplan-Meier analysis for RFS by recurrence risks defined by
recurrence risk (dashed line) by the Cox proportional hazards model demo
recurrence risk (solid line) in both the (A) discovery (p = 0.0036 by log rankspecificity = 75%), the two groups had significant separ-
ation of RFS (p< 0.0001, Figure 3B).miRNAs show potential in monitoring for melanoma
recurrence
To evaluate the clinical feasibility of using circulating miR-
NAs in post-resection surveillance for recurrence, we first
measured the expression of 7 miRNAs, selected from our
prioritized panel of 11 miRNAs based on previously sup-
ported roles in cancer progression and/or diagnostic utility
and from tissue-based miRNA studies supporting an asso-
ciation with melanoma progression [27,28], in 10 matched
serum samples collected pre- and post-resection of primary
melanoma. Mean expression levels of all 7 miRNAs were
reduced after operation, but only the difference in mean ex-
pression of miR-221, -222 and −423-5p reached statistical
significance (p <0.05). Next, we measured the expression of
these miRNAs in pre- and post-recurrence serum samples
from a subset of the discovery cohort (n=17). Serum levels
of all 7 miRNAs were increased, with mean expression of 2
miRNAs (miR-103 and −221) showing statistically signifi-
cant post-recurrence elevation (p <0.025, Figure 4).Discussion
We present the first study demonstrating the potential
prognostic value of serum miRNAs in melanoma. Specif-
ically, we provide evidence that serum miRNAs show
promise as biomarkers for improved identification of
high-risk melanoma patients at the time of primary diag-
nosis. By doing so, we introduce biological subclassifiers
that could add to the utility of clinical prognostic indica-
tors and help account for latent heterogeneity in melan-
oma. This is increasingly important as better adjuvantthe Cox proportional hazards model. Patients defined as high
nstrated significantly reduced RFS compared to patients defined as low
test) and (B) validation (p = 0.009 by log rank test) cohorts.
Figure 2 Kaplan-Meier analysis for RFS by recurrence risks defined by logistic regression risk model. Patients defined as high recurrence
risk (dashed line) by the logistic regression model demonstrated significantly reduced RFS compared to patients defined as low recurrence risk
(solid line) in both the (A) discovery (p < 0.0001 by log rank test) and (B) validation (p = 0.033 by log rank test) cohorts.
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target those likely to recur for aggressive treatment.
We identify miRNAs that are potential markers of dis-
ease progression in melanoma patients. In other malig-
nancies, such as colon, liver, testicular, prostate, and
ovarian cancers, serum tumor markers have become part
of the standard of care in surveillance for recurrence, at
times used in lieu of periodic imaging in asymptomatic
patients [34]. In melanoma, however, there are no widely
available circulating markers that can facilitate early de-
tection of relapse. Here, we show support for an associ-
ation between serum miRNAs and tumor burden, aFigure 3 Proof-of-principle logistic regression subgroup analysis of st
model defined for stage II patients had good classification performance (A
risk groups in stage II patients showed significant separation of RFS curvesfeature that if further developed, could be exploited by
incorporation of serum miRNAs assays in routine sur-
veillance for melanoma recurrence.
While there are several tissue-based and in vitro stud-
ies of miRNA dysregulation in melanoma [28,32,35-39],
little is known about the “source” of serum miRNAs
[19,21]. There is speculation that the source is not lim-
ited to the tumor and can include miRNAs shed from
the tumor microenvironment or from circulating im-
mune cells that also reflect the myriad of events involved
in the initiation and development of malignancy. This
suggests that, though tissue-based analyses are useful forage II patients. (A) ROC curve for the miRNA containing logistic risk
UC= 0.89). (B) Kaplan-Meier analysis for RFS of high and low recurrence
(p < 0.001 by log rank test).
Figure 4 Longitudinal evaluation of miRNA expression in pre- and post-recurrence serum samples. Difference between miRNA expression
levels of miR-103 and miR-221 at primary diagnosis and at recurrence was statistically significant (p = 0.012 and p= 0.026, respectively). The
horizontal axis represents time of blood draw for 17 patients. The vertical axis represents –(Ct) value.
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role for studying circulating miRNAs as an independent
source of biologically and clinically relevant information.
Growing interest in circulating miRNAs as biomarkers
has resulted in several studies exploring their potential in
solid tumors. However, the emphasis has been placed on
elucidating the diagnostic capabilities of blood-based miR-
NAs [16,17]. In melanoma, one group reported on serum
miR-221 levels and demonstrated a correlation with tumor
thickness [40]. The second used array screening to identify
unique miRNA expression profiles in peripheral blood
cells of melanoma patients compared to healthy controls
[35], which requires analysis of fresh blood specimens,
and limits the practicality of the approach.
While we are the first to identify the prognostic rele-
vance in melanoma of three of the miRNAs included in
the recurrence risk signature (miR-199a-5p, -33a, -424),
the biological function of all the identified miRNAs have
begun to be elucidated in tissue and in vitro studies.
miR-150 directly targets MUC4 in pancreatic cancer
cells, an aberrantly overexpressed transmembrane mucin
promoting growth, invasion and metastasis. miR-150
overexpression inhibits growth, clonogenicity, migration
and invasion, and enhances intracellular adhesion inpancreatic cancer cells [41]. Clinically, miR-150 was
elevated in melanoma tissues of patients with longer
post-recurrence survival [39], also supporting a tumor
suppressor role. Conflicting data exist regarding a pro-
proliferative effect of ectopic expression of miR-150 in
gastric cancer both in vitro and in vivo, at least in part
due to repression of the tumor suppressor EGR2, result-
ing in translational arrest [42]. Our findings are in
line with an oncogenic role for miR-150, with higher
circulating expression of miR-150 in patients with a high
recurrence risk. However, our findings can also be due
to the possibility that serum miRNAs reflect the sys-
temic immune response as miR-150 has a role in the
modulation of the T-cell development. Specifically, via
modulation of NOTCH3, overexpression of miR-150
has adverse effects on T-cell proliferation and survival,
resulting in decreased antitumor immunity and subse-
quent progression [43].
In our model, patients with high recurrence risk had
lower levels of miR-15b, similar to findings in a recent
study showing an association between reduced miR-15b
expression, chemotherapeutic resistance and poor prog-
nosis in patients with tongue squamous cell carcinoma
[44]. The same study identified BIM1 as a functional
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due to reduction of miR-15b regulates epithelial to mes-
enchymal transition and chemoresistence. Also in line
for a tumor suppressor role for miR-15b is its direct
regulation of the critical anti-apoptotic Bcl-2 protein
[45]. On the other hand, a previous study in melanoma
demonstrated that miR-15b downregulation in miR-15b
high melanoma cell lines resulted in decreased prolifera-
tion and increased apoptosis and clinically, found
increased tissue-based expression of miR-15b in melan-
oma FFPE samples from patients with shorter
recurrence-free and overall survival [31]. However, these
differences may be attributable to host-specific effects
reflected by measurement of circulating miRNAs as
opposed to solely tumor-specific effects.
While we are the first to demonstrate the prognostic
potential of miR-199a-5p in melanoma, with higher ex-
pression in high recurrence risk patients, its diagnostic
potential was supported by a study that found miR-
199a-5p overexpression in blood cells of melanoma
patients compared to healthy controls [35]. Our data,
taken with a recent study that found miR-199a-5p was
one of several miRNAs overexpressed in a small sample
of brain-metastatic compared to primary colorectal car-
cinomas [46], invites speculation that miR-199a-5p has a
role in the process of dissemination beyond its role in
carcinogenesis, which could in part be due to modula-
tion of Brm-type SWI/SNF activity [47]. Future studies
will be needed to further define the role of this miRNA
in cancer metastasis, and specifically in melanoma.
Strong evidence exists supporting a tumor suppressor
function for miR-33a via repression of proto-oncogene
Pim-1 [48] and inhibition of expression of cyclin-
dependent kinase 6 (CDK6) and cyclin D1 (CCDN1)
[49], both of which results in reduced cellular prolifera-
tion and cell-cycle progression. Though not previously
studied in melanoma, our data is also suggestive of a
tumor suppressive function for miR-33a, with lower
levels of miR-33a associated with high recurrence risk
scores. As with miR-33a, the prognostic or functional
relevance of miR-424 has not been studied in melanoma,
but roles have been previously defined for miR-424 in
HIF-1α/HIF-2α mediated angiogenesis [50] and regula-
tion of monocyte/macrophage differentiation [51]. Given
these roles of miR-424 in tumor formation and dissem-
ination (i.e. angiogenesis) and in systemic immune
responses, it is not surprising that, in measuring circu-
lating miRNAs, we found patients with high recurrence
risk to have elevated levels of miR-424 in the recurrence
risk model. Though the biological role and mechanistic
relationship of each of these components are not com-
pletely understood, particularly as they relate to melan-
oma, these miRNA prognostic classifiers can still be
clinically useful [52].The significant post-operative reduction and subse-
quent elevation at recurrence of the miRNAs identified
as having potential in detection of disease relapse (miR-
103, -221, -222, -423-5p) is consistent with existing data
delineating their roles in cancer progression. miR-103,
via downregulation of the enzyme Dicer, promotes cell
migration and invasion in breast cancer cells in vitro
[24]. Clinically, high levels of miR-103 are associated
with metastasis and poor outcome in breast cancer
patients [24]. In vitro and in vivo studies support onco-
genic roles for miR-221/222, which function to increase
invasion and migration capabilities as well as prolifera-
tive growth rate in melanoma by targeting of c-kit, p27,
and p57 [28]. Though the functional relevance and tar-
get genes of miR-423-5p have yet to be uncovered,
serum levels were significantly higher in gastric cancer
patients compared to healthy controls and it was identi-
fied as part of 5-miRNA signature for gastric cancer
diagnosis [26]. Together with our results that demon-
strate higher levels at the time of recurrence, we can
begin to speculate about a possible oncogenic role for
miR-432-5p.
We acknowledge that our study has several limitations.
First, we performed unbiased serum miRNA expression
profiling using a system demonstrated to have the high-
est sensitivity for analyzing serum miRNAs [23]. With
1,500+ transcribed miRNAs identified in the human
genome [16], the use of a panel containing 355 miRNA
assays could potentially be limiting. However, the miR-
NAs included were identified as being a comprehensive
set of miRNAs expressed in serum from extensive gen-
ome wide qPCR screening of normal and diseased sam-
ples, including melanoma patients [23]. Next, given the
expected imbalance in recurrence status among stage I
and III patients, we cannot speculate about a predictive
model that would work across all stages. However, we
are able to prioritize a manageable panel of miRNAs for
future testing that show potential as circulating biomar-
kers with clinical relevance in identifying primary melan-
oma patients at high risk for recurrence.
Conclusion
The evolving paradigm shift towards a molecular
characterization of melanoma to improve prognostic ac-
curacy, detect recurrence, and better guide management
decisions has largely been devoid of blood-based miRNA
studies. We show that serum-based miRNAs demon-
strate hallmarks of useful tumor markers, namely easy
detection in accessible samples and promising clinical
utility and applicability in melanoma. We demonstrate
support for the use of serum miRNAs as clinically useful
non-invasive biomarkers that could potentially enhance
the utility of current prognostic factors in predictive
models of melanoma recurrence. This would allow for
Friedman et al. Journal of Translational Medicine 2012, 10:155 Page 9 of 10
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could be influential in clinical decision-making. Specific-
ally, the development of serum miRNAs into clinical
assays can refine criteria for more extensive staging pro-
cedures, such as sentinel lymph node biopsy, and for in-
clusion in clinical trials. Moreover, the potential exists
for serum miRNAs to not only guide follow-up recom-
mendations and allow for better allocation of resources,
but also to improve the power of the current arsenal of
imaging and laboratory tests used in routine surveil-
lance. Future large prospective studies focusing on the
identified serum-based miRNAs stand to have a poten-
tially large clinical impact in aiding the early identifica-
tion of primary melanoma patients with high risk for
recurrence and in the timely detection of disease relapse.
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